Thursday, July 18, 2013
European researchers have obtained the
most compelling evidence yet that targeting sphingolipid metabolism could help
treat depression.1 The team has shown that two known antidepressants
inhibit sphingolipid metabolism and now is planning to screen for other
inhibitors that also elicit antidepressive effects.
The researchers first observed that
cultured human neurons treated with the generic SSRI antidepressants fluoxetine
and amitriptyline had lower in vitro SMPD1 activity and ceramide levels
than untreated neurons.
L. SciBX 6(27);
doi:10.1038/scibx.2013.675 Published online July 18, 2013
1. Gulbins, E. et al.
Nat. Med.; published online June 16, 2013; doi:10.1038/nm.3214 Contact:
Erich Gulbins, University of Duisburg-Essen, Essen, Germany e-mail: email@example.com
Contact: Johannes Kornhuber, University of Erlangen-Nuremberg, Erlangen,
Germany e-mail: firstname.lastname@example.org
2. Kornhuber, J. et al.
Cell Physiol. Biochem. 26, 9-20 (2010)
AND INSTITUTIONS MENTIONED
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
University of Erlangen-Nuremberg, Erlangen, Germany
University of Duisburg-Essen, Essen, Germany